Resveratrol ( DrugBank: Resveratrol )

6 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
8	Huntington disease	1
18	Spinocerebellar degeneration	2
89	Lymphangioleiomyomatosis	1
113	Muscular dystrophy	1
299	Cystic fibrosis	1

2. Amyotrophic lateral sclerosis

Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04654689 (ClinicalTrials.gov)	November 20, 2021	13/11/2020	Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients	Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients	Amyotrophic Lateral Sclerosis	Dietary Supplement: Liposomed polyphenols resveratrol and curcumin;Other: Placebo for liposomed resveratrol and curcumin;Dietary Supplement: Isocaloric Diet;Drug: G04CB02;Other: Placebo microcrystalline methylcellulose	Fundación Universidad Católica de Valencia San Vicente Mártir	NULL	Recruiting	18 Years	75 Years	All	60	Phase 2	Spain
2	EUCTR2021-001989-38-ES (EUCTR)	08/07/2021	14/06/2021	COMPARISON OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE IMPROVEMENT OF PATIENTS WITH ELA WHO ARE BEING TREATED WITH RILUZOLE	IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE - IMCRELA	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Dutasterida Product Name: Dutasterida INN or Proposed INN: DUTASTERIDE Other descriptive name: DUTASTERIDE	Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Spain

8. Huntington disease

Clinical trials : 229 / Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02336633 (ClinicalTrials.gov)	July 2015	8/1/2015	Resveratrol and Huntington Disease	Metabolic Intervention Using Resveratrol in Patients With Huntington Disease	Huntington Disease	Dietary Supplement: Resveratrol;Other: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	102	N/A	France

18. Spinocerebellar degeneration

Clinical trials : 71 / Drugs : 99 - (DrugBank : 30) / Drug target genes : 45 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03933163 (ClinicalTrials.gov)	May 23, 2019	16/4/2019	Micronised Resveratrol as a Treatment for Friedreich Ataxia	A Randomised Placebo-controlled Crossover Trial of Micronised Resveratrol as a Treatment for Friedreich Ataxia	Friedreich Ataxia	Drug: Resveratrol	Murdoch Childrens Research Institute	NULL	Active, not recruiting	16 Years	N/A	All	40	Phase 2	Australia
2	NCT01339884 (ClinicalTrials.gov)	April 2011	14/4/2011	A Study of Resveratrol as Treatment for Friedreich Ataxia	An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia	Friedreich Ataxia	Drug: Resveratrol	Murdoch Childrens Research Institute	Friedreich's Ataxia Research Alliance	Completed	18 Years	N/A	Both	27	Phase 1/Phase 2	Australia

89. Lymphangioleiomyomatosis

Clinical trials : 39 / Drugs : 46 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03253913 (ClinicalTrials.gov)	March 31, 2018	10/8/2017	Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial	Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)	Lymphangioleiomyomatosis	Drug: Sirolimus;Drug: Resveratrol	University of Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Unknown status	18 Years	N/A	Female	25	Phase 2	United States

113. Muscular dystrophy

Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000014836	2014/05/01	12/08/2014	A pilot study to evaluate efficacy and safety of resveratrol for muscular dystrophy.		Duchenne muscular dystrophy, Becker muscular dystrophy, Fukuyama congenital muscular dystrophy	500mg resveratrol is administrated daily for 8 weeks. Subsequently, resveratrol is increased to 1500mg by 500mg every 8 weeks.	Sapporo Medical University	NULL	Complete: follow-up complete	12years-old	Not applicable	Male and Female	10	Not selected	Japan

299. Cystic fibrosis

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04166396 (ClinicalTrials.gov)	February 17, 2020	14/11/2019	Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis	Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Resveratrol;Dietary Supplement: NR;Dietary Supplement: Placebo	Virginia Commonwealth University	NULL	Recruiting	18 Years	N/A	All	36	N/A	United States